ADMIRALEN AS

12 crawlable comparisons of consecutive annual reports.

Full company analysis · Org.nr 914 240 433

Cash halved-plus

2024 → 2025

Comparing Årsregnskap 2025 with 2024 for ADMIRALEN AS. Net result +10.2k NOK → +18.9k NOK. Equity 925.4k NOK → 944.3k NOK.

A steady year on the published lines

2023 → 2024

Comparing Årsregnskap 2024 with 2023 for ADMIRALEN AS. Net result +1 124 NOK → +10.2k NOK. Equity 915.1k NOK → 925.4k NOK.

Returned to profit, cash halved-plus

2022 → 2023

Comparing Årsregnskap 2023 with 2022 for ADMIRALEN AS. Net result -41.7k NOK → +1 124 NOK. Equity 914.0k NOK → 915.1k NOK.

Weaker earnings

2021 → 2022

Comparing Årsregnskap 2022 with 2021 for ADMIRALEN AS. Net result -2 884 NOK → -41.7k NOK. Equity 955.6k NOK → 914.0k NOK.

Stronger earnings

2020 → 2021

Comparing Årsregnskap 2021 with 2020 for ADMIRALEN AS. Net result -1.09m NOK → -2 884 NOK. Equity 958.5k NOK → 955.6k NOK.

Weaker earnings

2019 → 2020

Comparing Årsregnskap 2020 with 2019 for ADMIRALEN AS. Revenue 0 NOK → 0 NOK (0.0%). Net result -92.1k NOK → -1.09m NOK. Equity 855.6k NOK → 958.5k NOK.

Slipped into loss, cash halved-plus

2018 → 2019

Comparing Årsregnskap 2019 with 2018 for ADMIRALEN AS. Revenue 0 NOK → 0 NOK (0.0%). Net result +6 689 NOK → -92.1k NOK. Equity 791.8k NOK → 855.6k NOK.

Shrank 100% on revenue

2017 → 2018

Comparing Årsregnskap 2018 with 2017 for ADMIRALEN AS. Revenue 10.39m NOK → 0 NOK (-100.0%). Equity 5.73m NOK → 791.8k NOK.

Shrank 32% on revenue

2016 → 2017

Comparing Årsregnskap 2017 with 2016 for ADMIRALEN AS. Revenue 15.18m NOK → 10.39m NOK (-31.6%). Equity 30.0k NOK → 5.73m NOK.

Grew 2447% on revenue

2015 → 2016

Comparing Årsregnskap 2016 with 2015 for ADMIRALEN AS. Revenue 596.2k NOK → 15.18m NOK (+2447.0%). Equity 38.5k NOK → 30.0k NOK.

Grew 430% on revenue

2014 → 2015

Comparing Årsregnskap 2015 with 2014 for ADMIRALEN AS. Revenue 112.5k NOK → 596.2k NOK (+429.9%). Equity 30.0k NOK → 38.5k NOK.

First published accounts

First year · 2014

First year in the published series for ADMIRALEN AS (2014). No prior-year comparative in this dataset.